Authors
Latest:
Results for First-Line Pembrolizumab in Advanced Urothelial CarcinomaArjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discusses biomarker findings and mature clinical results from KEYNOTE-052, which explored first-line pembrolizumab (Keytruda) in cisplatin-ineligible advanced urothelial carcinoma.
Latest:
MRD Assay Is New Step in Urothelial Cancer TestingA post hoc analysis from the IMvigor010 study evaluating circulating tumor ctDNA in patients receiving adjuvant atezolizumab in high-risk muscle-invasive urothelial cancer after surgery was presented at the European Society of Medical Oncology Immuno-Oncology Virtual Congress in 2020.
Latest:
Unlocking the Potential of Erdafitinib in Bladder Cancer TreatmentArlene O. Siefker-Radtke, MD, discusses the latest breakthroughs in bladder cancer treatment with erdafitinib, an FGFR1-4 inhibitor.
Latest:
Dr. Arlene Sharpe on the Discovery and Further Use of the PD-L1 PathwaySharpe, whose lab aided in the discover of the pathway, says blocking the pathway in order to treat cancers is important because it allows T cells to work better.
Latest:
Challenges Facing Geriatric Patients With Breast CancerArti Hurria, MD, director, Cancer and Aging Research Program, City of Hope, discusses challenges facing geriatric patients with breast cancer.
Latest:
Dr. Ashani T. Weeraratna on Aging and its Effects on How Melanoma Progresses and is TreatedAshani T. Weeraratna, PhD, discusses the similarities in treatment between younger and older patients with melanoma. She says this lack of differentiation between treatment regimens could pose a problem in the future. One such issue is that older patients tend to react less well to treatments like vemurafenib.
Latest:
Efficacy and Safety of High-Dose Interleukin-2 Treatment in Melanoma Patients with a History of Brain MetastasesThe purpose of this retrospective study is to evaluate tumor response rates and toxicity profiles of IL-2 therapy in a more contemporary cohort of patients with metastatic melanoma and a history of brain metastases.
Latest:
Considering Disease Risk Criteria When Choosing Systemic Therapy for Advanced RCCCombination therapies for patients with advanced renal cell carcinoma provides clinicians with new treatment avenues for their patients. To assess which path to go down, Tian Zhang, MD, MHS, and Randy F. Sweis, MD, led virtual discussions on evaluating patients’ risk criteria to determine their proper treatment.
Latest:
Grothey Shares Encouraging Data from Lead-In Phase of BEACON CRC TrialAxel Grothey, MD, discusses the results from the safety lead-in phase of the BEACON CRC trial investigating the triplet regimen of BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and anti-EGFR antibody cetuximab in patients with <em>BRAF</em>V600E-mutant metastatic colorectal cancer.
Latest:
The Outlook for JAK Inhibitors in MyelofibrosisAyalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the outlook for JAK inhibitors for patients with myelofibrosis.
Latest:
Dr. Nazha on a Mutational Model to Predict Response to Hypomethylating Agents in MDSAziz Nazha, MD, discusses a new mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).
Latest:
Clinical Trials Excite Treatment Landscape for Early-Stage EGFR-Mutated NSCLCBalazs Halmos, MD, MS, discusses 2 major presentations from the 2020 American Society of Clinical Oncology Virtual Scientific Program that appeared promising for the treatment of patients with EGFR-mutant non–small cell lung cancer.
Latest:
Treatment of Patients With HPV Associated Locally Advanced Oropharynx CancerBarbara A. Burtness, MD, professor of medicine, clinical research program leader, Head and Neck Cancers Program, co-director, Developmental Therapeutics Research Program, Yale Cancer Center, discusses the treatment of patients with HPV associated locally advanced oropharynx cancer.
Latest:
Ongoing Trials Studying Immunotherapy as a First-Line Treatment in Head and Neck CancerBarbara Ann Burtness, MD, professor of medicine, Clinical Research Program Leader, Head and Neck Cancers Program and Co-Director, Developmental Therapeutics Research Program at Yale Cancer Center, discusses the ongoing trials looking at immunotherapy as a first-line treatment in head and neck cancer.
Latest:
An Analysis of Ovarian Cancer CareBarbara Ann Goff, MD, discusses an analysis looking at the care of ovarian cancer.
Latest:
Advanced Melanoma Responds Well to Pembrolizumab/Ipilimumab CombinationA regimen of pembrolizumab (Keytruda) and low-dose ipilimumab (Yervoy) was effective, and tolerable, for patients with advanced melanoma, according to results from the phase Ib KEYNOTE-029 clinical trial presented by lead investigator Georgina Long, BSc, PhD, MBBS.
Latest:
Dr. Barbara Burtness on the Psychology of Talking to Patients About Enrolling in Clinical TrialsBurtness says on average, medical professionals should take about 4 minutes or longer to properly explain the clinical trial to their patients, as well as leave ample time for questions at the end of the conversation.
Latest:
Patient-Centered Management of Metastatic Renal Cell CarcinomaThe development of drugs that target angiogenesis and signal transduction pathways in the treatment of metastatic renal cell carcinoma (RCC) has led to improved survival rates for patients.
Latest:
EGFR Mutations in Patients With Lung CancerBarbara J. Gitlitz, MD, associate professor of clinical medicine, Keck Medicine, University of Southern California, discusses EGFR mutations in patients with lung cancer.
Latest:
Insights on Multiple Myeloma From Ola Landgren, MD, PhDIn the treatment of multiple myeloma (MM), following decades of little progress, the last 10 years have been characterized by more clinical advancements than for any other cancer.
Latest:
Minimal Residual Disease (MRD) Marches to Front Line of Myeloma ResearchMore than two dozen abstracts at the December 2013 meeting of the American Society of Hematology (ASH) focused on the detection, measurement, or monitoring of MRD in patients with multiple myeloma.
Latest:
How Oral Targeted Therapies and IV Immunotherapies Disrupted Community Practice FinancingBarbara McAneny, MD, the chief executive officer of New Mexico Cancer Center, discusses how oral targeted therapies and immunotherapies disrupted the traditional methods for financing community practices.
Latest:
Comparison of Cologuard With Other CRC Screening ToolsBarry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses how the Cologuard test compares with other screening tools for colorectal cancer.
Latest:
Overcoming Financial Toxicities of Cancer CareBarry Russo, CEO, The Center for Cancer and Blood Disorders, discusses ways to overcome financial toxicities associated with the cost of cancer care.
Latest:
Mutational Abnormalities in MDSBart L. Scott, MD, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses breakthrough topics in myelodysplastic syndromes (MDS), such as mutational abnormalities.
Latest:
Challenges Impacting Treatment of Cutaneous and Peripheral T-Cell LymphomasBasem William, MD, discusses challenges in treating patients with cutaneous and peripheral T-cell lymphomas, as well as the challenges in conducting clinical trials in this patient population.
Latest:
Choosing Second-Line Therapy for HER2+ Gastric CancerBassel El-Rayes, MD, discusses how he approaches second-line therapy for patients with HER2-positive gastric cancer.
Latest:
CPI-613 in Combination With High Dose ARA-C and MitoxantroneBayard L. Powell, MD, discusses a phase I study that looked at CPI-613 in combination with high dose ARA-C and mitoxantrone for the treatment of patents with relapsed/refractory acute myeloid leukemia (AML).
Latest:
Effects of the Affordable Care ActBen Jones from McKesson Specialty Health discusses how the affordable care act will affect oncologists.
